Cntf Gene is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
{{infobox gene
| name = Ciliary Neurotrophic Factor
| symbol = CNTF
| chromosomal_location = 11q12.2
| ncbi_gene_id = 1270
| ensembl_id = ENSG00000261349
| uniprot_id = P26441
| omim_id = 118945
| associated_diseases = Amyotrophic Lateral Sclerosis, Alzheimer's Disease, Parkinson's Disease, Multiple Sclerosis, Retinitis Pigmentosa, Spinal Cord Injury, Stroke
}}
CNTF encodes ciliary neurotrophic factor (CNTF), a neuroprotective cytokine belonging to the interleukin-6 family. CNTF promotes the survival and differentiation of various neuronal populations and has been investigated as a potential therapeutic for neurodegenerative diseases.[1] Unlike most neurotrophic factors, CNTF is not secreted via the classical secretory pathway but is stored in cytoplasm and released upon cell injury, making it an "injury-related" neuroprotective factor.
CNTF is a neuroprotective cytokine with multiple mechanisms of action:
- Protein Class: Neurotrophic factor, cytokine (IL-6 family)
- Molecular Weight: ~23 kDa (depending on preparation)
- Receptor Complex: CNTFRα + gp130 + LIFRβ
- Signaling Pathways: JAK/STAT3, MAPK/ERK, PI3K/Akt
- Neuronal Survival: Prevents apoptotic cell death in motor neurons, sensory neurons, and hippocampal neurons[2]
- Differentiation: Promotes differentiation of oligodendrocyte precursors into mature oligodendrocytes
- Synaptic Plasticity: Modulates neurotransmitter function and synaptic connectivity[3]
- Anti-inflammatory: Reduces neuroinflammation through microglial modulation
- Axonal Regeneration: Promotes axonal outgrowth in injured peripheral neurons
CNTF binds to a tripartite receptor complex:
- CNTFRα: Ligand-binding subunit (specific to CNTF)
- gp130: Signal-transducing subunit (shared with IL-6 family)
- LIFRβ: Co-receptor for signal transduction
Signaling cascades activated:
- JAK/STAT3 pathway: Primary pro-survival signaling
- MAPK/ERK pathway: Promotes neuronal differentiation
- PI3K/Akt pathway: Anti-apoptotic signaling
- CNTF provides neuroprotection to motor neurons[4]
- Clinical trials of CNTF in ALS showed modest effects but limited by side effects
- AAV-mediated CNTF delivery being investigated in preclinical models
- CNTF levels reduced in ALS patient spinal cord
- CNTF protects hippocampal neurons from amyloid-beta toxicity[5]
- Improves synaptic function and memory in AD models
- Being explored as therapeutic agent in combination approaches
- CNTF counteracts Aβ-induced neuronal apoptosis
- CNTF protects dopaminergic neurons in substantia nigra[6]
- Shows promise in MPTP and 6-OHDA models
- Delivery challenges to midbrain being addressed with AAV vectors
- Combined GDNF/CNTF approaches show synergistic effects
- Promotes oligodendrocyte precursor differentiation[7]
- Remyelination potential in demyelination models
- Being investigated in animal models of MS
- Anti-inflammatory effects may reduce autoimmune attack
- Protects photoreceptor neurons from degeneration
- Clinical trials using encapsulated cell therapy (NT-501)
- Shows promise in preserving visual acuity
- Delivery via intraocular implant
- Promotes axonal regeneration and functional recovery
- Combines neuroprotective and anti-inflammatory effects
- Being tested in combination with rehabilitation
- Reduces infarct size in animal models
- Promotes neurogenesis and angiogenesis
- Therapeutic window of several hours post-stroke
- Brain: Astrocytes, Schwann cells, olfactory ensheathing cells
- Peripheral Nervous System: Schwann cells
- Non-neural: Heart, skeletal muscle, kidney, liver
| Cell Type |
Expression Level |
Notes |
| Astrocytes |
High |
Major source in CNS |
| Schwann cells |
High |
PNS support cells |
| Olfactory ensheathing cells |
Moderate |
Regeneration support |
| Microglia |
Low |
Inflammatory response |
- CNTF 1, 2, 3 trials: Early ALS trials (1990s) - mixed results, side effects
- NT-501 trial: Encapsulated cell therapy for retinitis pigmentosa
- AAV-CNTF trials: Preclinical for ALS and PD
- Recombinant protein: Limited by blood-brain barrier
- AAV-mediated gene therapy: Long-term expression, being refined
- Encapsulated cell therapy: Controlled CNTF release
- Cell therapy: Neural stem cells engineered to secrete CNTF
- Side effects from systemic CNTF (weight loss, cough)
- Delivery to CNS remains challenging
- Immune response to foreign protein
- Optimal dosing and timing unclear
- Sendtner M, et al. (1992). Ciliary neurotrophic factor prevents degeneration of motor neurons. Nature. PMID:1565864.
- Siegel GJ, et al. (2000). Neurotrophic factors in Alzheimer's disease. Prog Brain Res. PMID:11027402.
- Azzouz M, et al. (2004). Gene therapy for ALS using CNTF. J Neurosci. PMID:15056622.
- Dittrich F, et al. (1996). CNTF and ALS. Ann Neurol. PMID:8826418.
- Kumar VB, et al. (2000). CNTF and amyloid toxicity. Neurobiol Aging. PMID:10958967.
- Escott KJ, et al. (1998). CNTF and dopaminergic neurons. Neuroscience. PMID:9712654.
- Stankoff B, et al. (2002). CNTF and oligodendrocyte differentiation. Dev Neurosci. PMID:12490557.
- Zhang Y, et al. (2011). AAV-CNTF for ALS. Mol Ther. PMID:21556051.
- Tao J, et al. (2016). CNTF and neuroinflammation. J Neuroinflammation. PMID:27554259.
- Weber M, et al. (2019). Encapsulated cell therapy for RP. Ophthalmology. PMID:30658903.
The study of Cntf Gene has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
[1] Sendtner M, et al. Ciliary neurotrophic factor prevents degeneration of motor neurons. Nature. 1992;358(6386):502-504. PMID:1565864.
[2] Ip NY, et al. CNTF receptors and signaling mechanisms. Annu Rev Neurosci. 1993;16:169-191. PMID:8395019.
[3] Stoop R, et al. CNTF and synaptic plasticity. Neuroscientist. 2001;7(5):400-411. PMID:11645096.
[4] Dittrich F, et al. Clinical trials of CNTF in ALS. Ann Neurol. 1996;40(3):459-466. PMID:8826418.
[5] Kumar VB, et al. Ciliary neurotrophic factor mediates amyloid-beta toxicity. Neurobiol Aging. 2000;21(4):503-510. PMID:10958967.
[6] Escott KJ, et al. Ciliary neurotrophic factor protects dopaminergic neurons. Neuroscience. 1998;84(4):1117-1125. PMID:9712654.
[7] Stankoff B, et al. CNTF promotes oligodendrocyte differentiation. Dev Neurosci. 2002;24(1-3):85-93. PMID:12490557.
[8] Zhang Y, et al. AAV-CNTF gene therapy for ALS. Mol Ther. 2011;19(7):1318-1326. PMID:21556051.
[9] Tao J, et al. CNTF modulates neuroinflammation. J Neuroinflammation. 2016;13(1):285. PMID:27854259.
[10] Weber M, et al. Encapsulated cell therapy for RP. Ophthalmology. 2019;126(4):523-534. PMID:30658903.